Biortus USA, Inc.

Biortus USA, Inc. Custom and Pre-Selected Recombinant Protein Products and services to Fit Your Budget and Needs!

Biortus is a leading world-class contract research organization that provides one-stop service of gene synthesis to structure determination. Since 2009, Biortus has partnered worldwide with numerous research institutions, and pharmaceutical and biotechnology companies - consistently providing high-quality custom proteins for all stages of biomedical research. In addition to Custom Protein Generati

on, our subsidiary, Biortus USA now provides rapidly available crystallography-grade proteins in the Biortus Protein Catalogue to better serve the global life science industry. Many of these proteins have been crystallized and/or structurally elucidated using our in-house X-ray and Cryo-EM facilities. The Biortus Protein Catalogue currently comprises of over 1,900 independent drug targets, consisting of Membrane Proteins, Kinases, ubiquitin-proteasome enzymes (DUBS and E3 Ligases), CDKs (cyclin and cyclin-dependent kinases), and more, covering a wide range of therapeutic areas. All protein samples are individually packaged with detailed quality control reports of protein solubility, purity, and stability with optional reports on functional activity based on client needs.

08/21/2026

🔬 New Structure Release from Biortus Structural Biology Library
Protein: TNIK (TRAF2 and NCK-interacting kinase)
📈 Resolution: 2.70 Å
🧪 Method: X-ray Crystallography

Biortus is excited to announce the successful determination of the high-resolution crystal structure of TNIK at 2.70 Å.

TNIK is a key regulator of the Wnt/β-catenin and Hippo signaling pathways and has emerged as a promising therapeutic target in oncology and neurodegenerative disease research. The availability of this high-quality structure provides valuable insights for structure-based drug design (SBDD) and target-focused drug discovery. Based on the email draft, the structure was determined by X-ray crystallography at 2.70 Å resolution.

Why Biortus?
✅ 3,000+ crystallization conditions with automated robotic setup
✅ Weekly synchrotron beamline access for rapid data collection
✅ Extensive experience supporting SBDD programs
📺 Explore more structures on our YouTube channel: https://www.youtube.com//playlists

📩 Contact us: [email protected] | [email protected]

08/10/2026

Biortus Structural Biology Library New Releases
Protain: FASN| Resolution: 2.18 Å | Method: X-ray Diffraction

Biortus proudly announces the high-resolution crystal structure of FASN (Fatty Acid Synthase), determined at 2.18 Å by X-ray crystallography.

Fatty Acid Synthase (FASN), a key lipid-metabolizing enzyme, catalyzes the production of saturated fatty acids from acetyl-CoA and malonyl-CoA. It modulates the survival, differentiation, and function of multiple immune cells, thereby playing a role in the pathogenesis of immune-related diseases. Aberrant FASN expression and its synthesized fatty acids are observed in tumors, cardiovascular disorders, and inflammatory and autoimmune diseases.

Biortus has successfully determined the high-resolution apo FASN structure, providing key structural information to guide structure-based drug design and facilitating the rational development and optimization of FASN-targeted small-molecule inhibitors.

Biortus X-ray Crystallography Advantages
✅ 3,000+ crystallization conditions with robotic setup
✅ Weekly synchrotron beamline access for rapid data
✅ Proven partner in structure-based drug design (SBDD)
________________________________________
📧 Want to Learn More?
Watch our structure YouTube channel at: https://www.youtube.com//playlists
Contact us at: [email protected] | [email protected]

08/03/2026

High-Resolution Cryo-EM Structures Reveal the Assembly Pathway of HSP60

How does HSP60 assemble into its functional double-ring chaperonin complex?

Capturing the transient intermediates that form during this process has remained a major challenge in structural biology. Our team at Biortus has successfully resolved the cryo-EM structures of three closed-ring HSP60 oligomeric states:
🔹 Hexamer (2.83 Å)
🔹 Heptamer (3.22 Å)
🔹 Tetradecamer double-ring assembly (2.61 Å)

Notably, clear ATP density was observed in all three structures, providing valuable insights into the molecular mechanism of HSP60 assembly and function.

The structures have been deposited in the EMDB:
• EMD-69938
• EMD-69945
• EMD-69952

This work highlights Biortus' capability in resolving complex macromolecular assemblies and multiple conformational states through high-resolution Cryo-EM.

As the world's largest commercial Cryo-EM facility, Biortus is equipped with multiple Titan Krios G4 systems, supported by Glacios, Talos, and TF20 platforms. Our scientists have extensive experience delivering atomic-resolution structural insights for proteins, protein complexes, membrane proteins, and ligand-bound targets.

Interested in advancing your structural biology or drug discovery program?
📧 Contact us at [email protected]
🎥 Explore our Cryo-EM resources on the Biortus YouTube channel: https://www.youtube.com//playlists

12/01/2025

Biortus is proud to announce the successful determination of the human adenosine receptor A3AR in complex with the ligand CF101 in its active conformation at an outstanding 2.81 Å resolution using cryo-electron microscopy (Cryo-EM).

The A3AR–CD39 signaling axis plays a critical role in brain repair associated with vascular dementia (VaD). CF101 (Piclidenoson)—a selective A3AR agonist currently in Phase III clinical trials for psoriasis—has demonstrated the ability to promote brain tissue regeneration and improve memory and motor function, pointing to a promising therapeutic strategy for VaD.

The A3AR–CF101 cryo-EM structure solved by Biortus (EMD-66627, 2.81 Å) is the highest-resolution structure available in this receptor family within the EMDB. The map resolves side-chain interactions within the A3AR binding pocket with exceptional clarity, revealing how CF101 engages and activates the receptor—providing an important structural framework for understanding CF101-mediated signaling and receptor activation.

This achievement further strengthens Biortus’s position as a global leader in structural biology and drug discovery. As the world’s largest commercial Cryo-EM facility, Biortus is equipped with multiple Titan Krios G4 instruments, supported by Glacios, Talos, and TF20 platforms, and a team of expert scientists experienced in solving atomic-resolution structures of large and complex biomolecules.

🔬 Want to explore more of our Cryo-EM work?
Contact us at [email protected], or visit the Biortus YouTube channel to explore our Cryo-EM playlist and other high-resolution breakthroughs: 👉 https://www.youtube.com//playlists

10/27/2025

🚀 New Structure Release from Biortus Structural Biology Library

We’re excited to share the high-resolution crystal structure of LANCL2 (Lanthionine Synthetase C-Like Protein 2), solved at 2.15 Å by X-ray crystallography.

🧬 Why LANCL2 matters
LANCL2 is an abscisic acid (ABA) receptor expressed in immune, epithelial, and muscle cells. It regulates insulin sensitivity, glucose metabolism, and immune responses through NF-κB inhibition.
Its dysregulation has been linked to metabolic disorders, inflammatory diseases, and cancer — making this structure a valuable foundation for LANCL2-targeted drug discovery.

🔬 Biortus X-ray Crystallography Advantages
✅ 3,000+ crystallization conditions with robotic setup
✅ Weekly synchrotron beamline access for rapid data collection
✅ Proven partner in structure-based drug design (SBDD)

🎥 Explore more Biortus structures on YouTube:
👉 Biortus Structural Biology Channel

📩 Contact us: [email protected] | [email protected]

10/14/2025

🚀 New Structure Release from Biortus!

We’re thrilled to announce the addition of NIK (NF-κB–inducing kinase) to the Biortus Structural Biology Library — resolved at 2.9 Å using X-ray crystallography.

🧬 Why it matters:
NIK regulates the noncanonical NF-κB pathway, influencing immune responses, viral replication, and cancer development. This new high-resolution structure (including its ligand-bound complex) opens doors for structure-based drug design (SBDD) targeting NIK.

✨ Why Biortus:

3,000+ crystallization conditions

Weekly synchrotron access

Fast, high-quality results for SBDD projects

📺 Learn more: https://www.youtube.com//playlists
📧 Contact: [email protected] | [email protected]

Team Biortus is heading to BioJapan 2025!We’re thrilled to be part of BioJapan 2025 – Asia’s premier bio-industry partne...
09/29/2025

Team Biortus is heading to BioJapan 2025!

We’re thrilled to be part of BioJapan 2025 – Asia’s premier bio-industry partnering event – taking place in Yokohama, Japan, October 8–10.

📍 Visit us at Booth C29 to meet our colleagues Minqi Gao and Dr. Yifan Hu, and explore the latest advancements in Biortus’s services, products, and platforms. Don’t miss the opportunity to discuss how our innovative solutions can accelerate your drug discovery journey.

We look forward to seeing you in Yokohama!

📩 Schedule a meeting: [email protected]

09/09/2025

🎉 Exciting News — Biortus Brand-New Website is LIVE! 🚀

New Vision. New Possibilities.

We’re thrilled to introduce our new digital home — designed to give you a seamless experience exploring who we are and what we do:

✨ BiortusAI – From Prediction to Precision: Integrating Protein Design, Antibody Optimization & Lead Molecule Discovery.
✨ Four Platforms, Total Control – End-to-end workflow integration: Gene Synthesis → Protein Production → Assay & Screening → X-ray Crystallography → Cryo-EM.
✨ Product Hub, Now Live! – Your instant access to breakthrough science: 6000+ Recombinant Proteins, 300+ Membrane Proteins, 30+ Assay Kits, 20+ Tool Enzymes.

While our look has evolved, our mission remains the same: to empower drug discovery teams with the expertise, tools, and trusted partnerships needed to overcome today’s toughest structural biology challenges.

👉 Explore the new site: www.biortus.bio — your one-stop solution, now at your fingertips.

Meet Team Biortus at the Discovery on Target (DOT) Conference in Boston, MA!We’re excited to sponsor Discovery on Target...
09/08/2025

Meet Team Biortus at the Discovery on Target (DOT) Conference in Boston, MA!

We’re excited to sponsor Discovery on Target (DOT) 2025, where top scientists and innovators spotlight the latest hot targets and the technologies driving the future of drug discovery.
📍 Sheraton Boston, MA
📅 Sept 22–25, 2025

👉 Meet Team Biortus at Booth #313 — let’s talk about how we can advance discovery together!

🎤 Don’t miss our talk, Dr. Daniel Turman, Sr. Director of Business Development, presenting:“Tapping into Structure-Enabled Drug Discovery Targeting GPCRs”
📆 Thursday, Sept 25 | 12:45–1:00 PM

Let’s connect, collaborate, and shape the next chapter of drug discovery! 📩 Reach us at [email protected]

Address

5 Walnut Hill Park, STE 13
Woburn, MA
01801

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+17812878695

Website

Alerts

Be the first to know and let us send you an email when Biortus USA, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Biortus USA, Inc.:

Shortcuts

Share

Category